Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI reads CT scans to predict lung cancer comeback

NCT ID NCT07552532

Knowledge-focused Sponsor: Guangming Lu Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at CT scans and other data from 2000 lung cancer patients to build a tool that predicts if the cancer will come back after surgery. The goal is to help doctors decide who needs closer monitoring. It is a retrospective study, meaning it analyzes past information rather than testing a new treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to a tool that helps doctors predict which lung cancer patients are at higher risk of recurrence after surgery, enabling more personalized follow-up and treatment plans.
What could go wrong
This is a retrospective study, meaning it looks back at existing data, not a prospective trial. The model may not work as well in real-world settings or different patient groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

2,000 people

The number who actually took part.

Started

Jan 2023

Expected to finish

Jun 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with pathologically confirmed non-small cell lung cancer (NSCLC) who underwent curative-intent surgical resection and had preoperative contrast-enhanced chest CT available were retrospectively identified from participating centers. Eligible patients had complete clinicopathological, imaging, and follow-up data for assessment of postoperative local recurrence.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Pathologically confirmed non-small cell lung cancer (NSCLC) 2. Preoperative contrast-enhanced chest CT performed within 2 weeks before surgery 3. Underwent routine postoperative follow-up Exclusion Criteria: 1. Small cell lung cancer or metastatic tumors 2. Incomplete resection (R1/R2) 3. No preoperative contrast-enhanced CT performed within 2 weeks before surgery 4. History of other malignancies 5. Inadequate follow-up or follow-up duration of 3 months or less

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lung cancer (NSCLC) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

lung cancer lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lung cancer (NSCLC)

Contacts and locations

Locations

  • Jinling Hospital

    Nanjing, Jiangsu, 210002, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.